Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2021)
Historic Cash & Equivalents for Cogent Biosciences (COGT) over the last 5 years, with Q3 2021 value amounting to $202.9 million.
- Cogent Biosciences' Cash & Equivalents rose 5676.71% to $202.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $202.9 million, marking a year-over-year increase of 5676.71%. This contributed to the annual value of $242.2 million for FY2020, which is 54715.16% up from last year.
- As of Q3 2021, Cogent Biosciences' Cash & Equivalents stood at $202.9 million, which was up 5676.71% from $218.1 million recorded in Q2 2021.
- In the past 5 years, Cogent Biosciences' Cash & Equivalents ranged from a high of $242.2 million in Q4 2020 and a low of $21.3 million during Q2 2020
- For the 5-year period, Cogent Biosciences' Cash & Equivalents averaged around $98.6 million, with its median value being $67.1 million (2018).
- As far as peak fluctuations go, Cogent Biosciences' Cash & Equivalents tumbled by 6179.58% in 2020, and later skyrocketed by 92195.2% in 2021.
- Quarter analysis of 5 years shows Cogent Biosciences' Cash & Equivalents stood at $36.9 million in 2017, then soared by 103.39% to $75.0 million in 2018, then tumbled by 50.12% to $37.4 million in 2019, then skyrocketed by 547.15% to $242.2 million in 2020, then decreased by 16.23% to $202.9 million in 2021.
- Its last three reported values are $202.9 million in Q3 2021, $218.1 million for Q2 2021, and $230.7 million during Q1 2021.